Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Smaller Drug Makers Chugai, Mitsubishi Tanabe Less Exposed To Bad Economy Than Big

This article was originally published in PharmAsia News

Executive Summary

Smaller Japanese drug makers have done a better job surviving the global economic crisis than have their larger competitors. Among the second-tier Japanese pharmaceuticals doing well in a troubled period are Chugai Pharmaceutical, Mitsubishi Tanabe Pharma and Tsumura, primarily because they are less exposed to economic conditions in other nations such as the United States. The small and midsize firms also have spent less than the larger ones on acquisitions in recent years that made them more exposed to a market downturn. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts